Search results for "Subcutaneous"

showing 10 items of 162 documents

Enhancement of brain choline levels by nicotinamide: mechanism of action

1998

Following the subcutaneous (s.c.) administration of nicotinamide (10 mmol/kg), the brain and CSF levels of nicotinamide were increased to millimolar concentrations, but the concentrations of N-methylnicotinamide (NMN) in the CSF, and of NMN and NAD+ in brain tissue were not significantly altered. Concomitantly, nicotinamide caused increases of the choline levels in the venous brain blood. In hippocampal slices, nicotinamide (1-10 mM) induced choline release in a calcium- and mepacrine-sensitive manner and, in [3H]choline-labelled slices, increased the levels of [3H]lyso-phosphatidylcholine and [3H]glycerophosphocholine. We conclude that nicotinamide enhances brain choline concentrations by …

MaleNiacinamidemedicine.medical_specialtyTime FactorsInjections Subcutaneouschemistry.chemical_elementIn Vitro TechniquesCalciumHippocampusCholinechemistry.chemical_compoundPhospholipase A2Internal medicinemedicineAnimalsCholineRats WistarPhospholipase AbiologyNicotinamideGeneral NeuroscienceBrainNADRatsB vitaminsEndocrinologyLiverchemistryNiacinamidebiology.proteinNAD+ kinaseNeuroscience Letters
researchProduct

Therapeutic Potential of Human Adipose-Derived Stem Cells (ADSCs) from Cancer Patients: A Pilot Study

2014

Mesenchymal stem cells from adipose tissue (ADSCs) are an important source of cells for regenerative medicine. The therapeutic effect of culture-expanded adipose derived stem cells has been shown; however, optimal xeno-free culture conditions remain to be determined. Cancer patients, specifically those undergoing invasive surgery, constitute a subgroup of patients who could benefit from autologous stem cell transplantation. Although regenerative potential of their ADSCs could be affected by the disease and/or treatment, we are not aware of any study that has evaluated the therapeutic potential of ADSCs isolated from cancer patients in reference to that of ADSCs derived from healthy subjects…

MalePathologyCellular differentiationmedicine.medical_treatmentCell Culture Techniqueslcsh:MedicineGene ExpressionAdipose tissuePilot ProjectsExosomesBiochemistryRegenerative medicineAutologous stem-cell transplantationAnimal CellsAdipocytesMedicine and Health Scienceslcsh:ScienceCells CulturedMultidisciplinaryPharmaceuticsStem CellsCell DifferentiationVesicle DeliveryStem-cell therapyMiddle AgedAdult Stem CellsAdipose TissueOncologyFemaleAnatomyCellular TypesResearch ArticleAdultUrologic Neoplasmsmedicine.medical_specialtyBiologyMesenchymal Stem Cell TransplantationTransplantation AutologousChondrocytesGeneticsmedicineHumansGene RegulationAgedOsteoblastsBiology and life scienceslcsh:RMesenchymal stem cellCancers and NeoplasmsMesenchymal Stem CellsCell BiologySubcutaneous Fat AbdominalTransplantationMicroRNAsGenitourinary Tract TumorsBiological TissueCell cultureCase-Control StudiesRNAlcsh:QDrug DeliveryPLoS ONE
researchProduct

Noradrenaline depleting and blood pressure lowering activity of threo-corbadrine

1968

Abstract Threo-corbadrine caused a long-lasting depletion of noradrenaline in the heart and in mesenteric vessels and lowered the blood pressure of normal and renal hypertensive rats. It is suggested that threo-cobadrine decreases vascular tone by acting peripherally as a substitute adrenergic transmitter.

MalePharmacologymedicine.medical_specialtyHypertension RenalChromatography PaperChemistryInjections SubcutaneousAdrenergicBlood PressureMethylationRatsVascular tonePlethysmographyNorepinephrineEndocrinologyBlood pressureEthanolaminesLevonordefrinInternal medicinemedicineAnimalsPlethysmographFluorometryBlood pressure loweringEuropean Journal of Pharmacology
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting …

2010

The objective of this study was to assess the effects of subcutaneous (sc) interferon beta-1a (IFNβ-1a) on cognition in mildly disabled patients with relapsing—remitting multiple sclerosis (RRMS). Patients aged 18—50 years with RRMS (McDonald criteria; Expanded Disability Status Scale score ≤4.0) were assigned IFNβ therapy at the physician’s discretion and underwent standardized magnetic resonance imaging, neurological examination and neuropsychological testing at the baseline and regular intervals for up to three years. This analysis included 459 patients who received sc IFNβ-1a (44 mcg: n = 236; 22 mcg: n = 223; three-year follow up was available for 318 patients). The hazard ratio for c…

Maleinterferon beta-1aKaplan-Meier EstimateRelapsing-RemittingNeuropsychological TestsCohort StudiesDisability EvaluationMedicineMale; Adolescent; Young Adult; Middle Aged; Kaplan-Meier Estimate; Cognition Disorders; Survival Analysis; Female; Disability Evaluation; Dose-Response Relationship Drug; Humans; Multiple Sclerosis Relapsing-Remitting; Prospective Studies; Cohort Studies; Disease Progression; Interferon-beta; Injections Subcutaneous; Neuropsychological Tests; Adult; Immunologic Factors; Endpoint DeterminationProspective StudiesProspective cohort studyinterferon beta multiple sclerosis cognitive impairmentSubcutaneousCognitive disorderHazard ratioMiddle AgedSettore MED/26 - NEUROLOGIANeurologyDisease ProgressionSettore MED/26 - NeurologiaFemaleDrugmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentEndpoint DeterminationInjections SubcutaneousLower riskInjectionsDose-Response RelationshipYoung AdultMultiple Sclerosis Relapsing-RemittingInternal medicineHumansImmunologic Factorscognitive functioncognitive impairmentExpanded Disability Status ScaleDose-Response Relationship Drugbusiness.industryInterferon beta-1aMcDonald criteriaOdds ratioInterferon-betamedicine.diseaseSurvival AnalysisSurgerydisabilityNeurology (clinical)businessCognition Disorderscognitive function; cognitive impairment; disability; disease progression; interferon beta-1a; multiple sclerosis
researchProduct

Subcutaneous emphysema, pneumomediastinum and pneumoperitoneum after diagnostic colonoscopy for ulcerative colitis: a rare but possible complication …

2010

Dear Editor: Colonoscopy is regarded as a safe procedure, but complications may occur. The most dreaded are perforation and massive bleeding of the colon. The incidence of perforation is low but, despite increased experience with the procedure, it remains unchanged over time and in a large population study ranges from 0.6 to 1 per 1.000 procedures, depending on the centre and the data source. Few studies have assessed risk factors for colonoscopy-related bleeding and perforation. Gatto et al. have reported that there was a significant trend in the incidence of perforation with increasing age, people aged 75 years or older having a fourfold risk as compared to those aged 65–69 years; same re…

Malemedicine.medical_specialtyAbdominal painmedicine.medical_treatmentPerforation (oil well)ColonoscopyPneumoperitoneumPneumoperitoneumLaparotomymedicinePneumomediastinumMediastinal EmphysemaAged 80 and overmedicine.diagnostic_testbusiness.industryRisk FactorGeneral surgeryGastroenterologyColonoscopymedicine.diseaseUlcerative colitisSubcutaneous EmphysemaSurgerySettore MED/18 - Chirurgia GeneraleColitis UlcerativeLaparoscopyAged 80 and over; Colitis Ulcerative; Colonoscopy; Humans; Laparoscopy; Male; Mediastinal Emphysema; Pneumoperitoneum; Risk Factors; Subcutaneous Emphysema; Gastroenterologymedicine.symptombusinessSubcutaneous emphysemaHumanInternational Journal of Colorectal Disease
researchProduct

Improvement of treatment adherence with growth hormone by easypod™ device: experience of an Italian centre

2018

Abstract Background One of the most important vulnerabilities falling the efficacy of recombinant human growth hormone (r-hGH) treatment is low adherence especially in young patients. This study was planned to describe the correlation between r-hGH treatment efficacy and adherence in real-life setting using easypod™. Methods Forty patients younger than 18 years, affected by a clinical condition in which r-hGH is available and treated with r-hGH easypod™, were enrolled in a retrospective, observational, real-world data, monocentric trial. The study design provided the retrospective collection of records collected by a questionnaire proposed to the patients and their parents and compared with…

Malemedicine.medical_specialtyAdolescentTreatment adherenceInjections SubcutaneousTurner syndrome030209 endocrinology & metabolismSelf AdministrationInjections SubcutaneouGrowth hormone deficiencyMedication Adherence03 medical and health sciencesEasypod™0302 clinical medicinePatient satisfactionDrug Delivery SystemsGrowth DisorderRetrospective StudieInternal medicineTurner syndromemedicineHumansTreatment adherence030212 general & internal medicineChildGrowth DisordersRetrospective StudiesR-hGHbusiness.industryHuman Growth HormoneResearchlcsh:RJ1-570Retrospective cohort studylcsh:PediatricsSmall for gestational ageRecombinant Proteinmedicine.diseaseRecombinant ProteinsPatient SatisfactionChild PreschoolPediatrics Perinatology and Child HealthSmall for gestational ageObservational studyFemaleGrowth hormone deficiencybusinessSelf-administrationDrug Delivery SystemHumanItalian Journal of Pediatrics
researchProduct

Psychological insulin resistance in geriatric patients with diabetes mellitus.

2013

To determine the extent to which geriatric patients with diabetes mellitus experience psychological insulin resistance (PIR).A total of 67 unselected geriatric patients with diabetes (mean age 82.8±6.7 years, diabetes duration 12.2 [0.04-47.2] years, 70.1% female) were recruited in a geriatric care center of a university hospital. A comprehensive geriatric assessment (CGA) was performed including WHO-5, Hospital Anxiety and Depression Scale (HADS), Mini Mental State Examination (MMSE) and Barthel-Index. We assessed PIR using the Barriers of Insulin Treatment Questionnaire (BIT) and the Insulin Treatment Appraisal Scale in a face-to-face interview.Insulin-naïve patients (INP) showed higher P…

Malemedicine.medical_specialtyHealth Knowledge Attitudes Practicemedicine.medical_treatmentInjections SubcutaneousHospital Anxiety and Depression ScaleInsulin resistanceQuality of lifeInternal medicineDiabetes mellitusSurveys and QuestionnairesmedicineHumansHypoglycemic AgentsInsulinPsychiatryGeriatric AssessmentDepression (differential diagnoses)AgedAged 80 and overPsychiatric Status Rating ScalesDepressive DisorderMini–Mental State Examinationmedicine.diagnostic_testbusiness.industryDepressionInsulinGeneral MedicineFearPatient Acceptance of Health CareUniversity hospitalmedicine.diseaseDiabetes Mellitus Type 2Quality of LifeFemaleInsulin ResistancebusinessPatient education and counseling
researchProduct

Similar rewarding effects of testosterone in mice rated as short and long attack latency individuals.

2002

An attempt was made to confirm and extend the findings of an earlier study on the rewarding properties of testosterone in male mice using conditioned place preference (CPP). Previous results had only partially demonstrated such an effect because the reinforcement depended on environmental cues such as the colour of the compartment. High individual variability was evident, suggesting that basal levels of aggressiveness may modulate such effects. Animals were pre-screened for aggressive behaviour and allocated to short and long attack latency (SAL and LAL) categories. Five days later the CPP procedure started. This involved pre-conditioning tests, conditioning and post-conditioning tests. SAL…

Malemedicine.medical_specialtyInjections SubcutaneousMedicine (miscellaneous)Male miceDevelopmental psychologyBasal (phylogenetics)MiceRandom AllocationRewardInternal medicineTestosterone treatmentConditioning PsychologicalmedicineAnimalsTestosteroneLatency (engineering)ReinforcementPharmacologyBehavior AnimalTestosterone (patch)Conditioned place preferenceAggressionPsychiatry and Mental healthEndocrinologyConditioningPsychologyReinforcement PsychologyAddiction biology
researchProduct

Chest Surgery for Transgender and Gender Nonconforming Individuals

2018

Chest surgery can greatly facilitate the experience of living in a gender role. For transfeminine chest surgery, most surgeons recommend a 12-month period of feminizing hormone therapy prior to breast augmentation. For those who already have some breast volume due to hormone treatment, lipofilling can be a good option. Transmasculine chest surgery includes mastectomy and creation of a male chest. Preoperative parameters to be evaluated include breast volume, degree of excess skin, nipple-areola complex size and position, and skin elasticity. The algorithm the authors developed and modified can help choose from 5 techniques, resulting in an aesthetically pleasing male chest.

Malemedicine.medical_specialtyMammaplastymedicine.medical_treatmentSubcutaneous mastectomy030230 surgeryTransgender Persons03 medical and health sciencesChest surgery0302 clinical medicineTransgenderHumansMedicineThoracoplastyChest surgeryBreast augmentationSubcutaneous MastectomyMastectomybusiness.industryBreast augmentationmedicine.diseaseSurgeryGynecomastia030220 oncology & carcinogenesisMammaplastyTransgenderFemaleSurgeryHormone therapybusinessTranssexualismMastectomyHumanClinics in Plastic Surgery
researchProduct